Small Cell Prostate Cancer Clinical Trials

The clinical trials on this list are for prostate cancer treatment.

Small cell prostate cancer clinical trials.

The eligibility criteria which is meant to ensure patients safety may include the patient s age gender cancer type and stage previous treatments and overall health. The purpose of this research study is to assess the impact of 68ga psma 11 pet ct an experimental imaging scan for prostate cancer on the success of. Non small cell lung cancer or prostate cancer that has spread to other. Nci s basic information about clinical trials explains the types and phases of trials and how they are carried out.

For cohort a scnc. Clinical trials are research studies that involve people. This is a multi institutional single arm open label phase 2 trial evaluating mln8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer. Aggarwal identified a sub type that became prevalent in 17 of patients who were heavily pretreated with enzalutamide xtandi and abiraterone zytiga he calls this treatment emergent small cell neuroendocrine prostate cancer t scnc the pre treatment probably selected for this subtype that may be partially responsive to.

Not all neuroendocrine prostate cancers carry the same prognosis. Although all clinical trials have criteria for the participants clinical trials are available to patients at all stages of cancer. Patients with de novo small cell prostate cancer are not required to have received androgen deprivation therapy adt. Clinical trials also known as clinical studies or research protocols are conducted to test whether a new drug new prevention strategy or new screening test is safe and effective in people.

A clinical research study is now enrolling men with recurrent prostate cancer after radical prostatectomy who have a psa of at least 0 1 ng ml and are planned to undergo salvage radiotherapy. An antigen often expressed by several different types of cancers cea. Research and clinical trials. Cancer vaccine targets under evaluation in prostate cancer clinical trials include.

All trials on the list are supported by nci. Subjects will be treated with mln8237 at 50 mg twice daily for 7 days repeated every 21 days. A protein involved in cellular adhesion that is normally produced only before birth but is often abnormally expressed in cancer and may contribute to metastasis. Participation is always voluntary.

The proposed clinical trial will study the effects of 12 months of therapy with arn 509 alone or in combination with an lhrh agonist lhrha each compared to lhrha alone in men with a rapidly rising serum psa after prior definitive local therapy for prostate cancer. Clinical trials look at new ways to prevent detect or treat disease.